Cebranopadol, a Novel First-in-Class Analgesic Drug Candidate: First Experience With Cancer-Related Pain for up to 26 Weeks-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cebranopadol, a Novel First-in-Class Analgesic Drug Candidate: First Experience With Cancer-Related Pain for up to 26 Weeks

Published:2019-09 Issue:3 Volume:58 Page:390-399
ISSN:0885-3924
Container-title:Journal of Pain and Symptom Management
language:en
Short-container-title:Journal of Pain and Symptom Management

Author:

Koch E. Dietlind,Kapanadze Sofia,Eerdekens Marie-Henriette,Kralidis Georg,Létal Jiří,Sabatschus Ingo,Ahmedzai Sam H.

Funder

Grünenthal GmbH

Publisher

Elsevier BV

Subject

Anesthesiology and Pain Medicine,Neurology (clinical),General Nursing

Reference25 articles.

1. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study;Bray;Lancet Oncol,2012

2. Early integration of palliative care services with standard oncology care for patients with advanced cancer;Greer;CA Cancer J Clin,2013

3. Treatment of cancer pain;Portenoy;Lancet,2011

4. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis;van den Beuken-van Everdingen;J Pain Symptom Manage,2016

5. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes;Breivik;Ann Oncol,2009

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Opioids in the Setting of Acute Postoperative Pain: A Narrative Review;Pharmaceuticals;2023-12-25

2. Naturally Inspired Molecules for Neuropathic Pain Inhibition—Effect of Mirogabalin and Cebranopadol on Mechanical and Thermal Nociceptive Threshold in Mice;Molecules;2023-11-30

3. IUPHAR Review - Bivalent and bifunctional opioid receptor ligands as novel analgesics;Pharmacological Research;2023-11

4. Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and mitigation of the misuse crisis;BJA Open;2023-06

5. Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics;Drugs;2023-05-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3